Combined sevoflurane-dexmedetomidine and nerve blockade on post-surgical serum oxidative stress biomarker levels in thyroid cancer patients

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 10

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Cases. Apr 6, 2022; 10(10): 3027-3034
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3027

Table 4 Toxicity and side effect rate in the two groups, n (%)

Group	Headache	Ataxia	Drowsiness	Toxicity and side effect rate
Experimental group (n = 49)	2 (4.08)	2 (4.08)	1 (2.04)	5 (10.20)
Control group (n = 47)	1 (2.13)	3 (6.38)	2 (4.26)	6 (12.76)
χ²	-	-	-	0.155
P value	-	-	-	0.694

Citation: Du D, Qiao Q, Guan Z, Gao YF, Wang Q. Combined sevoflurane-dexmedetomidine and nerve blockade on post-surgical serum oxidative stress biomarker levels in thyroid cancer patients. World J Clin Cases 2022; 10(10): 3027-3034
URL: https://www.wjgnet.com/2307-8960/full/v10/i10/3027.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i10.3027

Du D, Qiao Q, Guan Z, Gao YF, Wang Q. Combined sevoflurane-dexmedetomidine and nerve blockade on post-surgical serum oxidative stress biomarker levels in thyroid cancer patients. World J Clin Cases 2022; 10(10): 3027-3034 [PMID: 35647114 DOI: 10.12998/wjcc.v10.i10.3027]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.